Dasatinib

Pharmacogenomic Information in the Context of the FDA-Approved Drug Label*

The FDA requires testing for Philadelphia chromosome-positive status and resistance or intolerance to prior therapy prior to initiating treatment of acute lymphoblastic leukemia (ALL) with dasatinib.

Excerpt from the dasatinib drug label:

"SPRYCEL is also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy."

Dasatinib is a protein kinase inhibitor whose substrates include the BCR-ABL kinase encoded by the Philadelphia chromosome. Dasatinib is used to treat patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) who are resistant or intolerant to other therapies, such as treatment with imatinib.

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Dasatinib drug label PDF.

Related PharmGKB Resources: